Burden of illness and treatment attitudes among participants meeting Rome IV criteria for irritable bowel syndrome: A nationwide survey in the United States

被引:1
作者
Lacy, Brian E. [1 ]
Xu, Yanqing [2 ]
Taylor, Douglas C. A. [3 ]
Kosch, Katherine J. [2 ]
Dobrescu, Rachel [4 ]
Morlock, Amy [4 ]
Morlock, Robert [5 ]
Rooker, Ceciel [6 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Ironwood Pharmaceut, Boston, MA USA
[4] Acumen Hlth Res Inst, Ann Arbor, MI USA
[5] YourCareChoice, Ann Arbor, MI USA
[6] Int Fdn Gastrointestinal Disorders, Milwaukee, WI USA
关键词
abdominal pain; constipation; diarrhea; functional GI diseases; irritable bowel syndrome (IBS); RETROSPECTIVE ANALYSIS; GLOBAL PREVALENCE; ECONOMIC BURDEN; HEALTH; MANAGEMENT; CONSTIPATION; VALIDITY; ARTICLE; IMPACT; IBS;
D O I
10.1111/nmo.14903
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by abdominal pain and altered bowel habits, with patient-perceived dissatisfaction of treatment symptom control. We assessed disease burden, satisfaction with medication use, and impact on activities, in participants with IBS with constipation (IBS-C) and diarrhea (IBS-D). Methods: This study assessed data from a large, United States survey of adults querying demographics, comorbid conditions, quality of life, medication use, satisfaction with symptom control, and work productivity. Participants were grouped into the IBS-C or IBS-D cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self-reported. Key Results: Nine hundred and ten participants with IBS-C and 669 with IBS-D were matched to controls. The most reported symptoms were abdominal discomfort for IBS-C and abdominal pain and abdominal discomfort for IBS-D. Among the IBS-C and IBS-D cohorts, 74.2% and 65.9%, respectively, took prescription and/or over-the-counter medication for their symptoms. Respondents were more dissatisfied than satisfied with control of their symptoms. Respondents taking prescription medication(s) with or without over-the-counter medication(s) reported better symptom control than respondents only taking over-the-counter medications (p < 0.001). There was significantly higher mean presenteeism, work productivity loss, and daily activity impairment (p < 0.001 for all) in respondents with IBS compared with controls. Conclusions and Inferences: This study provides insight into respondents' experiences of IBS symptoms, including the impact on daily activity, as well as satisfaction with control of symptoms and prescription and over-the-counter medications.
引用
收藏
页数:13
相关论文
共 34 条
[1]   Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey [J].
Ballou, Sarah ;
McMahon, Courtney ;
Lee, Ha-Neul ;
Katon, Jesse ;
Shin, Andrea ;
Rangan, Vikram ;
Singh, Prashant ;
Nee, Judy ;
Camilleri, Michael ;
Lembo, Anthony ;
Iturrino, Johanna .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (12) :2471-+
[2]   Best management of irritable bowel syndrome [J].
Black, Christopher J. ;
Ford, Alexander Charles .
FRONTLINE GASTROENTEROLOGY, 2021, 12 (04) :303-315
[3]   Recent advances in the treatment of irritable bowel syndrome [J].
Bonetto, Silvia ;
Fagoonee, Sharmila ;
Battaglia, Edda ;
Grassini, Mario ;
Saracco, Giorgio Maria ;
Pellicano, Rinaldo .
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (7-8) :709-715
[4]  
Buono JL, 2017, J MANAG CARE SPEC PH, V23, P435, DOI 10.18553/jmcp.2016.16138
[5]   Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea [J].
Buono, Jessica L. ;
Carson, Robyn T. ;
Flores, Natalia M. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2017, 15
[6]   Management Options for Irritable Bowel Syndrome [J].
Camilleri, Michael .
MAYO CLINIC PROCEEDINGS, 2018, 93 (12) :1858-1872
[7]   Review article: the economic impact of the irritable bowel syndrome [J].
Canavan, C. ;
West, J. ;
Card, T. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (09) :1023-1034
[8]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[9]   Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment [J].
Corsetti, Maura ;
Brown, Steven ;
Chiarioni, Giuseppe ;
Dimidi, Eirini ;
Dudding, Thomas ;
Emmanuel, Anton ;
Fox, Mark ;
Ford, Alexander C. ;
Giordano, Pasquale ;
Grossi, Ugo ;
Henderson, Michelle ;
Knowles, Charles H. ;
O'Connell, P. Ronan ;
Quigley, Eamonn M. M. ;
Simren, Magnus ;
Spiller, Robin ;
Whelan, Kevin ;
Whitehead, William E. ;
Williams, Andrew B. ;
Scott, S. Mark .
NEUROGASTROENTEROLOGY AND MOTILITY, 2021, 33 (07)
[10]   Impact of Rome IV Irritable Bowel Syndrome on Work and Activities of Daily Living [J].
Goodoory, Vivek C. ;
Ng, Cho Ee ;
Black, Christopher J. ;
Ford, Alexander C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) :844-856